Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.29
MNKD's Cash to Debt is ranked lower than
92% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. MNKD: 0.29 )
Ranked among companies with meaningful Cash to Debt only.
MNKD' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.33 Max: No Debt
Current: 0.29
F-Score: 1
Z-Score: -38.83
M-Score: -12.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA (%) -183.75
MNKD's ROA (%) is ranked lower than
94% of the 955 Companies
in the Global Biotechnology industry.

( Industry Median: -27.67 vs. MNKD: -183.75 )
Ranked among companies with meaningful ROA (%) only.
MNKD' s ROA (%) Range Over the Past 10 Years
Min: -141.48  Med: -70.42 Max: -54.14
Current: -183.75
-141.48
-54.14
ROC (Joel Greenblatt) (%) -325.72
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: -358.44 vs. MNKD: -325.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNKD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -285.89  Med: -96.5 Max: -70.3
Current: -325.72
-285.89
-70.3
EBITDA Growth (3Y)(%) 3.30
MNKD's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. MNKD: 3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNKD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -43  Med: -25.4 Max: 10.9
Current: 3.3
-43
10.9
EPS Growth (3Y)(%) -1.10
MNKD's EPS Growth (3Y)(%) is ranked higher than
53% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -3.60 vs. MNKD: -1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNKD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: -22.9 Max: 7.6
Current: -1.1
-42.9
7.6
» MNKD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MNKD Guru Trades in Q3 2015

Paul Tudor Jones 43,922 sh (New)
Murray Stahl 217,952 sh (+39.98%)
» More
Q4 2015

MNKD Guru Trades in Q4 2015

Paul Tudor Jones 219,364 sh (+399.44%)
Murray Stahl 380,440 sh (+74.55%)
» More
Q1 2016

MNKD Guru Trades in Q1 2016

Murray Stahl Sold Out
Paul Tudor Jones 103,372 sh (-52.88%)
» More
Q2 2016

MNKD Guru Trades in Q2 2016

Paul Tudor Jones 103,325 sh (-0.05%)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GNIXF, NAS:PTI, NAS:CLSD, OTCPK:TYMI, NAS:OVAS, NAS:SQNM, NAS:PRTK, NAS:ESPR, NAS:SYRS, NAS:CRBP, NAS:SELB, NAS:CXRX, NAS:FOMX, NAS:IMMU, NAS:RXDX, OTCPK:SPHDF, NAS:BSTC, NAS:CMRX, NAS:EDGE, NAS:CRIS » details
Traded in other countries:NNF1.Germany,
MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.

MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.

Ratios

vs
industry
vs
history
EV-to-EBIT -1.31
MNKD's EV-to-EBIT is ranked lower than
99.99% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 23.08 vs. MNKD: -1.31 )
Ranked among companies with meaningful EV-to-EBIT only.
MNKD' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.2  Med: -4.7 Max: 0.9
Current: -1.31
-11.2
0.9
EV-to-EBITDA -1.34
MNKD's EV-to-EBITDA is ranked lower than
99.99% of the 258 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. MNKD: -1.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNKD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.2  Med: -5.1 Max: 1
Current: -1.34
-12.2
1
Current Ratio 0.31
MNKD's Current Ratio is ranked lower than
96% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.42 vs. MNKD: 0.31 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.41 Max: 12.24
Current: 0.31
0.12
12.24
Quick Ratio 0.30
MNKD's Quick Ratio is ranked lower than
95% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 4.19 vs. MNKD: 0.30 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.41 Max: 12.24
Current: 0.3
0.12
12.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.40
MNKD's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. MNKD: -14.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -42.5 Max: -8
Current: -14.4
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -76.30
MNKD's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: -8.80 vs. MNKD: -76.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNKD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 105.8  Med: 157.5 Max: 7504.7
Current: -76.3
105.8
7504.7

More Statistics

EPS (TTM) $ -0.89
Beta2.29
Short Percentage of Float34.83%
52-Week Range $0.61 - 3.79
Shares Outstanding (Mil)478.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.17 -0.15 -0.16
EPS w/o NRI ($) -0.17 -0.15 -0.16
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
MANNKIND CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Sep 22 2016
MNKD: How MannKind's Stock Price Fell 28% in 6 Months Sep 16 2016
MannKind Corp. :MNKD-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 Sep 14 2016
MannKind Stock: 3 Things to Watch (MNKD) Sep 13 2016
Short Sellers Run for Cover From Major Biotechs Sep 13 2016
The 6 Most Shorted Nasdaq Stocks: Short Sellers Get Choosy Sep 13 2016
Valencia company developing inhaler alternative to EpiPen Sep 06 2016
MannKind developing inhalable epinephrine to challenge Mylan's EpiPen Sep 06 2016
MannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference Sep 02 2016
MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says Aug 30 2016
Securities Class Action Against MannKind Dismissed Aug 25 2016
Securities Class Action Against MannKind Dismissed Aug 25 2016
Short Sellers Increase Bets in Major Biotechs Aug 25 2016
The 6 Most Shorted Nasdaq Stocks: Frontier in the Spotlight Aug 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)